PUMA BIOTECHNOLOGY, INC.: net property, plant and equipment
Net property, plant and equipment for PUMA BIOTECHNOLOGY, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PUMA BIOTECHNOLOGY, INC. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 187,000 | USD | 2026-02-26 | 10-K · 0001437749-26-005891 |
| At date | 2024-12-31 | 515,000 | USD | 2026-02-26 | 10-K · 0001437749-26-005891 |
| At date | 2023-12-31 | 855,000 | USD | 2025-02-27 | 10-K · 0001437749-25-005496 |
| At date | 2022-12-31 | 1,146,000 | USD | 2024-02-29 | 10-K · 0001437749-24-006121 |
| At date | 2021-12-31 | 1,756,000 | USD | 2023-03-02 | 10-K · 0001437749-23-005233 |
| At date | 2020-12-31 | 2,481,000 | USD | 2022-03-03 | 10-K · 0001437749-22-005164 |
| At date | 2019-12-31 | 3,304,000 | USD | 2021-03-01 | 10-K · 0001564590-21-009840 |
| At date | 2018-12-31 | 3,963,000 | USD | 2020-02-28 | 10-K · 0001564590-20-007591 |
| At date | 2017-12-31 | 4,470,000 | USD | 2019-03-01 | 10-K · 0001564590-19-005830 |
| At date | 2016-12-31 | 5,153,000 | USD | 2018-03-09 | 10-K · 0001564590-18-005152 |
| At date | 2015-12-31 | 2,383,000 | USD | 2017-03-01 | 10-K · 0001564590-17-003090 |
| At date | 2014-12-31 | 2,157,000 | USD | 2016-02-29 | 10-K · 0001564590-16-013716 |
| At date | 2013-12-31 | 1,684,000 | USD | 2015-03-02 | 10-K · 0001564590-15-001193 |
| At date | 2012-12-31 | 1,479,000 | USD | 2014-03-03 | 10-K · 0001193125-14-080183 |
| At date | 2011-12-31 | 682,000 | USD | 2013-04-01 | 10-K · 0001193125-13-136650 |
Related financial histories
- PUMA BIOTECHNOLOGY, INC.: total assets
- PUMA BIOTECHNOLOGY, INC.: total liabilities
- PUMA BIOTECHNOLOGY, INC.: stockholders equity
- PUMA BIOTECHNOLOGY, INC.: cash and cash equivalents
- PUMA BIOTECHNOLOGY, INC.: net income or loss
- PUMA BIOTECHNOLOGY, INC.: operating cash flow
- PUMA BIOTECHNOLOGY, INC.: capital expenditure payments
- PUMA BIOTECHNOLOGY, INC.: contract revenue excluding tax
- PUMA BIOTECHNOLOGY, INC.: financing cash flow
- PUMA BIOTECHNOLOGY, INC.: investing cash flow
- PUMA BIOTECHNOLOGY, INC.: retained earnings or deficit
- PUMA BIOTECHNOLOGY, INC.: basic weighted-average shares
- PUMA BIOTECHNOLOGY, INC.: diluted weighted-average shares
- PUMA BIOTECHNOLOGY, INC.: basic earnings per share
- PUMA BIOTECHNOLOGY, INC.: diluted earnings per share
- PUMA BIOTECHNOLOGY, INC.: income tax expense or benefit
- PUMA BIOTECHNOLOGY, INC.: share-based compensation expense
- PUMA BIOTECHNOLOGY, INC.: operating income or loss
- PUMA BIOTECHNOLOGY, INC.: current assets
- PUMA BIOTECHNOLOGY, INC.: interest expense
- PUMA BIOTECHNOLOGY, INC.: current liabilities
- PUMA BIOTECHNOLOGY, INC.: current accounts payable
- PUMA BIOTECHNOLOGY, INC.: net finite-lived intangible assets
- PUMA BIOTECHNOLOGY, INC.: net current accounts receivable
- PUMA BIOTECHNOLOGY, INC.: operating expenses
- PUMA BIOTECHNOLOGY, INC.: net inventory
- PUMA BIOTECHNOLOGY, INC.: selling, general and administrative expense
- PUMA BIOTECHNOLOGY, INC.: research and development expense
Inspect the source
- Entity
- PUMA BIOTECHNOLOGY, INC. / CIK 0001401667
- Captured
- 2026-09-20T08:00:41.213Z
- SEC response SHA-256
4b2b449f06e175eebf840b512ad515ef71296ad006f32415c1f427849828bc3d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001401667.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))